Pharmacogenomics
Robert T. Jones, Kenneth M. Felsenstein, Dan Theodorescu · Urologic Clinics of North America · 2015
Cited by 12 works. doi:10.1016/j.ucl.2015.08.007
Authors
References
- Global cancer statistics
- PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
- Molecular portraits of human breast tumours
- Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- Ki67 expression in breast cancer
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer
- Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
- Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study